Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions
Randomized, Controlled, Multi-center Trial to Evaluate the Efficacy, Tolerability, and Safety of an S-Ibuprofen Gel vs. Placebo in the Local Symptomatic and Short-Term Treatment of Pain in Acute Contusions of the Soft Tissues Following Blunt Trauma
Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in treatment of pain in acute contusions of the soft tissues following blunt trauma.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Bonn, Alemania, 53113
- Reclutamiento
- Dr. med Jürgen Ulrich Schaale-Maas
-
Contacto:
- Jurgen Schaale-Maas, Dr.med.
- Número de teléfono: +49 177 7373443
- Correo electrónico: jschaale@icloud.com
-
Bonn, Alemania, 53121
- Reclutamiento
- Orthopädische Praxis-Ebert
-
Contacto:
- Eduart Ebert, Dr. med.
- Número de teléfono: +49 173 7038059
- Correo electrónico: ebert.e@web.de
-
Gilching, Alemania, 82205
- Reclutamiento
- Dr. Helmut Pabst
-
Contacto:
- Helmut Pabst, Dr
- Número de teléfono: +49 814 123026
- Correo electrónico: h.pabst@pwc-gmbh.de
-
-
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97702
- Reclutamiento
- Northwest Foot Care - Amanda Westfall McCarty
-
Contacto:
- Amanda Westfall McCarty, DPM
- Número de teléfono: 541-385-7129
- Correo electrónico: amanda@nwfootcarebend.com
-
Bend, Oregon, Estados Unidos, 97702
- Reclutamiento
- Northwest Foot Care - Bryan Wilhelm
-
Contacto:
- Bryan Wilhelm, DPM
- Número de teléfono: 541-385-7129
- Correo electrónico: bwilh29@gmail.com
-
Bend, Oregon, Estados Unidos, 97702
- Reclutamiento
- Northwest Foot Care - Hayden Bush
-
Contacto:
- Hayden Bush, DPM
- Número de teléfono: 435-655-5127
- Correo electrónico: haydenbush91@gmail.com
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Acute soft-tissue injury/contusion.
- Enrollment within 6 hours of the injury.
- Baseline NRS score for POM of injured location >5 score points on an 11-point NRS.
- Size of injury, as assessed by the investigator, ≥25 cm2 and ≤120 cm2
- Adult male or female patients aged ≥18 years.
- Having given written informed consent.
- Satisfactory health as determined by the investigator based on medical history and physical examination.
Exclusion Criteria:
- Significant concomitant injury in association with the acute injury; e.g., fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound.
- Excessively hairy skin at application site, cutting the hair in the injured site prior to gel application will qualify for inclusion.
- Current skin disorder or shaving hair at application site.
- History of excessive sweating/hyperhidrosis inclusive of application site.
- Treatment with topical or systemic NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study.
- Intake of long-acting NSAIDs or application of topical medication since the injury (rest-ice-compression-elevation [RICE] is allowed).
- Participation in a clinical study within 30 days before inclusion in the study or concomitantly.
- Positive drug or alcohol screen or evidence of drug or alcohol abuse in the opinion of the investigator.
- Pregnant or lactating or intending to become pregnant during the study.
- Individuals of reproductive potential who do not agree to use of an acceptable birth control method throughout the study, when engaging in any sexual activity that comes with a risk of pregnancy.
- History of any allergy or hypersensitivity (e.g., anaphylaxis, urticaria/hives, rhinitis, skin reaction, asthma, angioedema, or other allergic symptoms) to acetaminophen, ibuprofen, other NSAIDs, or to 1 of the excipients of the gel.
- History of severe cutaneous adverse reactions to any medication, such as Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis.
- Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of S-ibuprofen gel 5%.
- History of previous significant injury to the same extremity within 6 months.
- Patients with a disease affecting the same area, such as synovitis, rheumatoid arthritis, arthrosis, etc.
- Patients experiencing symptoms of an infectious disease including swelling of any joint of the affected area.
- Patients having an ongoing painful condition associated with the injury/contusion.
- Patients who had surgery of the affected area within 1 year of study entry.
- Patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study; including patients with a history of gastrointestinal bleeding, significant cardiovascular, liver, or renal disease).
- Patients with a blood coagulation disorder.
- Patients who use any impermissible medication (eg. systemic or topical NSAIDs, analgesics (other than paracetamol), opiods, corticosteroids (except for topical treatment of bronchial asthma, heparin, or psychotropic agents)
- Patients who participated in previous clinical studies of S-ibuprofen gel 5% and patients of the same household.
- Patients who are related to those persons involved directly or indirectly with the conduct of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: S-Ibuprofen Topical Gel 5%
S-Ibuprofen Topical Gel 5% applied once per day to the affected injury site |
Topical gel containing active ingredient S-ibuprofen |
|
Comparador de placebos: Vehicle Topical Gel
Placebo Gel applied once per day to the affected injury site |
Placebo gel matching the active comparator in conposition and appearance without the active ingredient |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt trauma
Periodo de tiempo: 0-24 hours
|
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for pain-on-movement at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
0-24 hours
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to first perceptible pain relief based on direct questions to the patient and what they consider perceptible pain relief
Periodo de tiempo: From time 0 every 24 hours up to 7 days
|
Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
From time 0 every 24 hours up to 7 days
|
|
Time to onset of meaningful pain relief based on direct questions to the patient and what they consider meaningful pain relief
Periodo de tiempo: From time 0 to end of study (day 7)
|
Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
From time 0 to end of study (day 7)
|
|
Time gap between first perceptible pain relief and meaningful pain relief based on direct questions to the patient
Periodo de tiempo: From time 0 to end of study (day 7)
|
Calculated as a difference to reach perceptible vs meaningul pain relief. |
From time 0 to end of study (day 7)
|
|
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for spontaneous pain-on-movement (sPOM) at 24 hours
Periodo de tiempo: At 24 hours
|
Recorded in patient diary based on NRS scores for sPOM at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At 24 hours
|
|
Change from baseline for pain-at-rest (PAR) measured by numerical rating scale (NRS) at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
Based on NRS scores for PAR at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Change from baseline for pain-on-movement (POM) measured at Visit 3, Visit 4, Visit 5, and Visit 6
Periodo de tiempo: At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
Based on NRS scores for POM. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Change from baseline for spontaneous pain-on-movement measured at 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours
Periodo de tiempo: 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
|
When possible, recorded in patient diary. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
|
|
Pain-on-movement at the injured site recorded on a numerical rating scale (NRS) scale in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Sum of pain intensity differences (SPIDs) for pain-on-movement at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Baseline-adjusted area under the curve (AUC) for pain-on-movement at the injured site recorded on a numerical rating scale (NRS) in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Pain at rest measured by a numerical rating scale (NRS) at baseline at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
|
|
Time-specific pain intensity difference for spontaneous pain-on-movement at all time points
Periodo de tiempo: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for pain at rest at all time points
Periodo de tiempo: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study.NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for spontaneous pain on movement at all time points
Periodo de tiempo: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time-specific pain intensity difference for pain at rest at all time points
Periodo de tiempo: Time 0 to end of study (day 7)
|
Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete pain relief (Score = 0 pain)
Periodo de tiempo: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete resolution of pain-on-movement (Score = 0 pain)
Periodo de tiempo: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to complete resolution of pain at rest (Score = 0 of pain)
Periodo de tiempo: Time 0 to end of study (day 7)
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to end of study (day 7)
|
|
Time to the first request of rescue medication within the first 24 hours
Periodo de tiempo: Time 0 to 24 hours
|
If applicable |
Time 0 to 24 hours
|
|
Proportion of patients taking rescue medication per dosing interval and during the entire evaluation period
Periodo de tiempo: Time 0 to end of study (day 7)
|
If applicable |
Time 0 to end of study (day 7)
|
|
Responder rate (defined as the number of patients achieving 50% reduction from baseline in the NRS score for pain-on-movement at 24 hours)
Periodo de tiempo: Time 0 to 24 hours
|
NRS scale 0-10, 0=no pain, 10=worst possible pain. |
Time 0 to 24 hours
|
|
Global efficacy assessment by investigator (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
5-point Likert scale. 0 = excellent, 4 = very poor |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
|
Global efficacy assessments by patient (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Periodo de tiempo: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
5-point Likert scale. 0 = excellent, 4 = very poor |
At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
|
|
Overall dose of rescue medication
Periodo de tiempo: Time 0 to end of study (Day 7)
|
Rescue medication use will be assessed at every visit except Visit 1 |
Time 0 to end of study (Day 7)
|
|
Local tolerability at every visit except V1
Periodo de tiempo: Time 0 to end of study (day 7)
|
Examination for presence of erythema (0-3, 0 = none; 3 = severe), edema (0-3, 0 = none; 3 = severe), papiculation/vesiculation (0-3, 0 = none; 3 = severe), pruritus (NRS scale 0-10; 0 = no itch, 10 = worst possible itch), burning (NRS scale 0-10; 0 = no itch, 10 = worst possible itch) |
Time 0 to end of study (day 7)
|
|
Blood pressure exam at V1 and V6
Periodo de tiempo: At Visit 1 (time 0) and 6 (168 hours)
|
Systolic/diastolic blood pressure |
At Visit 1 (time 0) and 6 (168 hours)
|
|
Adverse events at every visit
Periodo de tiempo: Time 0 to end of study (day 7)
|
Time 0 to end of study (day 7)
|
|
|
Examination of pulse at V1 and V6
Periodo de tiempo: At Visit 1 (time 0) and 6 (168 hours)
|
Pulse measured as beats per minute |
At Visit 1 (time 0) and 6 (168 hours)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- AP-009
- 2025 (Subvención/contrato del NIH de EE. UU.)
- 2025-524451-31-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .